Surgivance
1 known investors
Surgivance develops digital pathology imaging technology for analyzing tissue samples with rapid image capture and without calibration requirements. The company serves pathology laboratories and medical professionals in the healthcare diagnostics field.
Investors · 1
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Science Foundation | Phase I | 2022 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $492.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Surgivance do?
- Surgivance develops digital pathology imaging technology for analyzing tissue samples with rapid image capture and without calibration requirements. The company serves pathology laboratories and medical professionals in the healthcare diagnostics field.
- Who are Surgivance's investors?
- Surgivance's investors include Portland Seed Fund.